Hims & Hers Broadens GLP-1 Access via Novo Nordisk Partnership
Event summary
- Hims & Hers is now offering a range of Novo Nordisk’s FDA-approved GLP-1 medications, including Wegovy, to eligible customers.
- The collaboration aims to provide more affordable access to GLP-1 medications with various dosages and delivery methods.
- Hims & Hers is introducing a new weight loss membership program starting at $39/month (plus medication costs).
- Prices for GLP-1 medications begin at $149 per month, requiring a Hims & Hers membership.
The big picture
This partnership represents a significant expansion for Hims & Hers, positioning them as a dominant player in the rapidly growing digital therapeutics and weight management market. Novo Nordisk’s willingness to partner with a direct-to-consumer platform signals a shift in pharmaceutical distribution strategies, potentially bypassing traditional pharmacy channels. The move also underscores the increasing consumer demand for accessible and affordable weight loss solutions, driven by the efficacy of GLP-1 medications.
What we're watching
- Pricing Pressure
- The $149/month starting price point, while seemingly affordable, will be under scrutiny as Hims & Hers scales and competition intensifies; margin compression is a risk if they need to lower prices to maintain volume.
- Clinical Oversight
- The reliance on provider clinical judgment for GLP-1 access creates a potential bottleneck and exposes Hims & Hers to liability if prescribing practices are deemed inappropriate or medically questionable.
- Compounding Risk
- The plan to offer compounded GLP-1s for a limited set of customers introduces regulatory and quality control risks that could damage Hims & Hers’ reputation and expose them to legal challenges.
Related topics